Patient characteristics
| Characteristics . | HGBL (N = 78) . | DLBCL (N = 354) . | P value . |
|---|---|---|---|
| Sex, n (%) | .191 | ||
| Female | 33 (42) | 120 (34) | |
| Male | 45 (58) | 234 (66) | |
| Age, median (range), y | 63 (55.5-68.0) | 60 (52.0-67-0) | .025 |
| Histology, n (%) | <.001 | ||
| HGBL-DH | 50 (64) | ||
| HGBL-NOS | 23 (30) | ||
| DLBCL MYC/BCL6 | 5 (6) | ||
| De novo | 278 (79) | ||
| Indolent transformed | 76 (21) | ||
| IPI, n (%) | .004 | ||
| 0-2 | 31 (40) | 205 (58) | |
| >2 | 47 (60) | 149 (42) | |
| LDH at infusion, n (%) | .765 | ||
| Normal | 46 (59) | 203 (57) | |
| Increased | 18 (23) | 90 (26) | |
| Missing | 14 (18) | 61 (17) | |
| CRP at infusion, n (%) | >.999 | ||
| <10 | 39 (50) | 176 (50) | |
| ≥10 | 39 (50) | 178 (50) | |
| ECOG at infusion n (%) | .899 | ||
| 0 | 47 (60) | 208 (59) | |
| ≥1 | 31 (40) | 146 (41) | |
| Disease status, n (%) | .217 | ||
| Relapsed | 18 (23) | 108 (31) | |
| Refractory | 60 (77) | 246 (69) | |
| No. of previous lines, n (%) | .353 | ||
| 1-2 | 56 (72) | 232 (66) | |
| >2 | 22 (28) | 122 (34) | |
| No. of extranodal sites, n (%) | >.999 | ||
| 0-2 | 66 (85) | 299 (84) | |
| >2 | 9 (11) | 42 (12) | |
| Missing | 3 (4) | 13 (4) | |
| Previous ASCT, n (%) | .332 | ||
| Yes | 18 (23) | 102 (29) | |
| No | 60 (77) | 252 (71) | |
| ORR to bridge, n (%) | .502 | ||
| No response | 49 (63) | 172 (49) | |
| Response | 25 (32) | 107 (30) | |
| Missing | 4 (5) | 75 (21) | |
| Bulky disease, n (%) | .063 | ||
| Yes | 33 (42) | 110 (31) | |
| No | 45 (58) | 244 (69) | |
| CAR T-cell therapy product, n (%) | >.999 | ||
| Axi-cel | 38 (49) | 172 (49) | |
| Tisa-cel | 40 (51) | 182 (51) | |
| Vein-to-vein time, median (range), mo | 1.6 (1.3-2.3) | 1.6 (1.4-2.3) | .639 |
| Time from diagnosis to infusion, median (range), mo | 12.7 (9.5-22.5) | 17.7 (11.2-43.3) | .002 |
| CAR-HEMATOTOX score, n (%) | .743 | ||
| Low (0-1) | 29 (37) | 144 (41) | |
| High (≥2) | 19 (24) | 83 (23) | |
| Missing | 30 (39) | 127 (36) |
| Characteristics . | HGBL (N = 78) . | DLBCL (N = 354) . | P value . |
|---|---|---|---|
| Sex, n (%) | .191 | ||
| Female | 33 (42) | 120 (34) | |
| Male | 45 (58) | 234 (66) | |
| Age, median (range), y | 63 (55.5-68.0) | 60 (52.0-67-0) | .025 |
| Histology, n (%) | <.001 | ||
| HGBL-DH | 50 (64) | ||
| HGBL-NOS | 23 (30) | ||
| DLBCL MYC/BCL6 | 5 (6) | ||
| De novo | 278 (79) | ||
| Indolent transformed | 76 (21) | ||
| IPI, n (%) | .004 | ||
| 0-2 | 31 (40) | 205 (58) | |
| >2 | 47 (60) | 149 (42) | |
| LDH at infusion, n (%) | .765 | ||
| Normal | 46 (59) | 203 (57) | |
| Increased | 18 (23) | 90 (26) | |
| Missing | 14 (18) | 61 (17) | |
| CRP at infusion, n (%) | >.999 | ||
| <10 | 39 (50) | 176 (50) | |
| ≥10 | 39 (50) | 178 (50) | |
| ECOG at infusion n (%) | .899 | ||
| 0 | 47 (60) | 208 (59) | |
| ≥1 | 31 (40) | 146 (41) | |
| Disease status, n (%) | .217 | ||
| Relapsed | 18 (23) | 108 (31) | |
| Refractory | 60 (77) | 246 (69) | |
| No. of previous lines, n (%) | .353 | ||
| 1-2 | 56 (72) | 232 (66) | |
| >2 | 22 (28) | 122 (34) | |
| No. of extranodal sites, n (%) | >.999 | ||
| 0-2 | 66 (85) | 299 (84) | |
| >2 | 9 (11) | 42 (12) | |
| Missing | 3 (4) | 13 (4) | |
| Previous ASCT, n (%) | .332 | ||
| Yes | 18 (23) | 102 (29) | |
| No | 60 (77) | 252 (71) | |
| ORR to bridge, n (%) | .502 | ||
| No response | 49 (63) | 172 (49) | |
| Response | 25 (32) | 107 (30) | |
| Missing | 4 (5) | 75 (21) | |
| Bulky disease, n (%) | .063 | ||
| Yes | 33 (42) | 110 (31) | |
| No | 45 (58) | 244 (69) | |
| CAR T-cell therapy product, n (%) | >.999 | ||
| Axi-cel | 38 (49) | 172 (49) | |
| Tisa-cel | 40 (51) | 182 (51) | |
| Vein-to-vein time, median (range), mo | 1.6 (1.3-2.3) | 1.6 (1.4-2.3) | .639 |
| Time from diagnosis to infusion, median (range), mo | 12.7 (9.5-22.5) | 17.7 (11.2-43.3) | .002 |
| CAR-HEMATOTOX score, n (%) | .743 | ||
| Low (0-1) | 29 (37) | 144 (41) | |
| High (≥2) | 19 (24) | 83 (23) | |
| Missing | 30 (39) | 127 (36) |
ASCT, autologous stem cell transplant; ECOG, Eastern Cooperative Oncology Group; FISH, fluorescence in situ hybridization; LDH, lactate dehydrogenase.
Nine patients in the HGBL subgroup were transformed from previous follicular NHL.